AGC Biologics has completed the expansion of its manufacturing space at the Milan Cell & Gene Center of Excellence production site.
The expansion added 1 x 50L, 2 x 200L and 2x 1,000L suspension single-use bioreactors, and allows for up to 4 iCellis500 adherent single-use bioreactors to meet demands for upcoming GMP viral vector manufacturing projects.
In addition, the project included the build-out of more process development lab space, a new automated filling line and the addition of a new fully dedicated 1,000m2 warehouse space.
“This is another important milestone for our site and for the AGC Biologics global Cell and Gene network as we prepare to serve more developers,” said Luca Alberici, General Manager, AGC Biologics Milan.
“Thanks to this expansion we have the flexibility to support companies from clinical to commercial stages for in–vivo end ex-vivo gene therapy applications and can manufacture adeno-associated and lentiviral vectors from medium 50L scales to as large as 2,000L.
“When you combine this with our development, analytical and fill/finish services, this site can offer cell and gene developers any type of support they need throughout their product’s lifecycle.”
AGC Biologics acquired the Milan site to launch its cell and gene business in July of 2020, and it has since become the global hub for its cell and gene therapy services.
